home / stock / vtyx / vtyx quote
Last: | $4.44 |
---|---|
Change Percent: | 2.06% |
Open: | $4.51 |
Close: | $4.44 |
High: | $4.62 |
Low: | $4.4 |
Volume: | 374,584 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.44 | $4.51 | $4.44 | $4.62 | $4.4 | 374,584 | 05-08-2024 |
$4.605 | $4.74 | $4.605 | $4.87 | $4.57 | 342,916 | 05-07-2024 |
$4.71 | $4.9 | $4.71 | $4.995 | $4.6197 | 433,687 | 05-06-2024 |
$4.85 | $5.05 | $4.85 | $5.24 | $4.85 | 853,274 | 05-03-2024 |
$4.91 | $4.76 | $4.91 | $5.17 | $4.5638 | 1,909,345 | 05-02-2024 |
$4.68 | $3.78 | $4.68 | $4.9125 | $3.7 | 2,269,491 | 05-01-2024 |
$3.74 | $3.8 | $3.74 | $3.96 | $3.7 | 2,856,835 | 04-30-2024 |
$3.835 | $3.94 | $3.835 | $4.045 | $3.82 | 947,340 | 04-29-2024 |
$3.93 | $4.04 | $3.93 | $4.08 | $3.925 | 529,730 | 04-26-2024 |
$4.06 | $4.15 | $4.06 | $4.15 | $3.94 | 586,706 | 04-25-2024 |
$4.24 | $4.32 | $4.24 | $4.45 | $4.22 | 375,984 | 04-24-2024 |
$4.35 | $4.34 | $4.35 | $4.42 | $4.26 | 444,784 | 04-23-2024 |
$4.3 | $4.5 | $4.3 | $4.54 | $4.23 | 1,100,280 | 04-22-2024 |
$4.47 | $4.33 | $4.47 | $4.63 | $4.26 | 906,049 | 04-19-2024 |
$4.35 | $4.37 | $4.35 | $4.48 | $4.235 | 849,902 | 04-18-2024 |
$4.38 | $4.76 | $4.38 | $4.7683 | $4.36 | 780,158 | 04-17-2024 |
$4.76 | $4.62 | $4.76 | $4.82 | $4.55 | 661,262 | 04-16-2024 |
$4.67 | $4.64 | $4.67 | $4.83 | $4.595 | 628,944 | 04-15-2024 |
$4.6 | $4.57 | $4.6 | $4.68 | $4.5 | 674,166 | 04-12-2024 |
$4.6 | $4.83 | $4.6 | $4.83 | $4.53 | 1,292,177 | 04-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focus...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a cl...